A clinical study has successfully completed recruitment of patients (Q1 2015) with locally advanced non-small cell lung cancer (NSCLC). Another clinical study in esophageal cancer has successfully completed recruitment of patients (Q4 2015) . Both studies has demonstrated BioXmark® to be well tolerated and perform as anticipated.
We are planning clinical studies in other indications incl. cancers of the bladder, prostate, liver, kidney, colon, rectum, pancreas and cervix uteri.
If you are interested in doing a clinical study with BioXmark® , please contact us using the contact form.